

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT5367833

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
SKU ASSET MANAGEMENT GMBH	01/04/2019
RECEIVING PARTY DATA	
Name:	SYNTAB THERAPEUTICS GMBH
Street Address:	SANKT-JOBSEK STRASSE 56
City:	WÜRSELEN
State/Country:	GERMANY
Postal Code:	52146
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	15255847
CORRESPONDENCE DATA	
Fax Number:	(678)420-9301
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	6784209300
Email:	salmona@ballardspahr.com
Correspondent Name:	SANDRA A. SCIASCIA-ZIRGER
Address Line 1:	999 PEACHTREE STREET
Address Line 2:	BALLARD SPAHR LLP, SUITE 1000
Address Line 4:	ATLANTA, GEORGIA 30309
ATTORNEY DOCKET NUMBER:	13318.0022U2
NAME OF SUBMITTER:	SANDRA A. SCIASCIA-ZIRGER
SIGNATURE:	/Sandra A. Sciascia-Zirger/
DATE SIGNED:	02/08/2019
Total Attachments: 2	
source=13318_0022U2_Assignment SKU_Syntab_US#page1.tif	
source=13318_0022U2_Assignment SKU_Syntab_US#page2.tif	

ASSIGNMENT
(U.S. RIGHTS ONLY)

WHEREAS, SKU ASSET MANAGEMENT GMBH, a corporation of Germany, whose principal address is Am Waldsaum 9, Baierbrunn, Germany 82065, is owner of the entire right, title and interest in "Novel Tumor-Targeting Compounds," for which a United States Patent Application was filed on September 2, 2016, and assigned 15/255,847;

WHEREAS, SYNTAB THERAPEUTICS GmbH, whose principal address is Sankt-Jobast StraÙe 56, 52146 Würselen, Germany, is desirous of acquiring the entire interest in the same;

NOW, THEREFORE, for good and valuable consideration, the receipt of which is hereby acknowledged, SKU ASSET MANAGEMENT GMBH, hereby do sell, assign and transfer unto said SYNTAB THERAPEUTICS GmbH, the entire right, title and interest in and to said invention and application in the United States, including, without limitation, any Letters Patent of the United States which may issue thereon and any subsequent U.S. application claiming priority to the above-identified application, reissue, reexamination, division, continuation-in-part, extension or continuation thereof; the same for SYNTAB THERAPEUTICS GmbH's legal representatives and assigns, as fully and entirely as the same would have been held by me had this assignment and sale not been made;

AND, SKU ASSET MANAGEMENT GMBH hereby binds itself, its legal representatives and assigns properly to execute without further consideration any and all applications, petitions, oaths and assignments or other papers and instruments which may be necessary in order to carry into full force and effect, the sale, assignment, transfer and conveyance hereby made or intended to be made and generally do everything possible to aid SYNTAB THERAPEUTICS GmbH's, its legal

representatives and assigns, to obtain and enforce proper protection for said invention in in the United States.

IN WITNESS WHEREOF, we have executed this assignment on the day indicated below.

SKU ASSET MANAGEMENT GMBH

By: A. Koll Date January 4th, 2019

Name Dr. Andre Koltermann

Title Managing Director, SKU Asset Management GmbH

ACCEPTED BY:

SYNTAB THERAPEUTICS GmbH

By: U. Steinboeck Date January 4th, 2019

Name Ute Steinboeck

Title Managing Director, Syntab Therapeutics GmbH